Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial

Journal of Dermatology

Volumn 43, Issue 3, 2016, Pages 288-293

  Umezawa, Yoshinori ^a   Nakagawa, Hidemi ^a   Tamaki, Kunihiko ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

22 oxacalcitriol ointment; maxacalcitol; palmoplantar pustulosis; randomized controlled trials

Indexed keywords

22 OXACALCITRIOL; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; GLUCOSE; PHOSPHORUS; PLACEBO; POTASSIUM; CALCITRIOL; DERMATOLOGICAL AGENT; OINTMENT;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE SWELLING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GLUCOSE URINE LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PUSTULOSIS PALMOPLANTARIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN IRRITATION; SYMPTOMATOLOGY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PSORIASIS; YOUNG ADULT;

ADULT; AGED; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940062492     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13064     Document Type: Article

References (11)

1. Lever WF,. Pustulosis palmaris et plantaris. In: Histopathology of the Skin, 4th edn. Lippincott, Philadelphia, 1967; 149-150.
2. Murakami M, Kaneko T, Nakatsuji T, et al,. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS ONE 2014; 16: e110677.
3. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H,. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20: 845-847.
4. Murakami M, Ohtake T, Horibe Y, et al,. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010; 130: 2010-2016.
5. Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G,. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163: 572-579.
6. 3 analogues. Chem Pharm Bull (Tokyo) 1986; 34: 4410-4413.
7. Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J,. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141: 274-278.
8. 3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res 1999; 291: 500-506.
9. Ozawa M, Terui T, Tagami H,. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology 2005; 211: 249-255.
10. Terui T, Ozawa M, Tagami H,. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000; 9: 1-10.
11. Terui T,. Inflammatory and immune reactions associated with stratum corneum and neutrophils in sterile pustular dermatoses. Tohoku J Exp Med 2000; 190: 239-248.